Samsung Electronics Shares Jump on HBM4 Mass Production Report 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
BOULDER, Colo., April 05, 2018 -- Biodesix®, Inc. will present new data confirming the ability of the company’s droplet digital PCR (ddPCR™)-based platform to reliably detect key mutations in blood for patients with lung cancer. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2018, taking place April 14-18 in Chicago, Ill.
“Blood-based molecular testing overcomes multiple limitations associated with tissue-based testing and is becoming an increasingly important component of care for cancer patients,” said David Brunel, Biodesix CEO. “In this study, we used the highly sensitive ddPCR technology to detect multiple EGFR variants reliably and reproducibly, while maintaining the rapid turnaround time that is characteristic of our testing methodology.”
Presentation details:
Title: Highly multiplexed diagnostic test for the detection of extended EGFR del19 variants in patients with NSCLC (Poster #5573/5)
Session Date/Time: Wednesday, April 18, 8:00 a.m.-12:00 p.m. Central Time
Authors: Hestia Mellert, Ph. D., Leisa Jackson, Ph. D, Kristin Alexander, Amanda Weaver, Dianna Maar, Dawne Shelton, Gary Pestano, Ph. D.
Location: Exhibit Hall A, McCormick Place South (Level 3), Poster Section 26, Liquid Biopsy 5
AACR 2018 meeting abstracts are currently available on the AACR website. The Biodesix AACR 2018 abstract is also available on Biodesix.com. The poster will be available after April 18.
About Biodesix®
Biodesix is a molecular diagnostics company advancing the development of innovative, multi-omic blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic liquid biopsy tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests and with the Biodesix Lung Reflex™ testing strategy, for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of personalized medicine, Biodesix is developing new tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.
For more information about Biodesix, please visit www.biodesix.com.
Contact: Rachel Biederman 720-214-5774 [email protected]
